carboplatin / Generic mfg. - LARVOL DELTA

Brief Report: First-line Chemoimmunotherapy and Chemotherapy Outcomes in Patients with RET Fusion-Positive Lung Cancer in LIBRETTO-431. (PubMed, J Thorac Oncol) - "In patients with advanced RET fusion-positive lung cancer treated in this global, multicenter trial, outcomes with first-line chemoimmunotherapy and chemotherapy were not significantly different in this secondary analysis. Using chemotherapy alone is a reasonable strategy for these oncogene-driven tumors. Based on the overall findings from LIBRETTO-431, selective RET inhibitors remain the preferred first-line therapy for patients with RET fusion-positive NSCLC."

Journal • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • PD-L1 • RET

Biomarker-Directed Sintilimab Monotherapy/combo in Untreated Advanced NSCLC: A Phase II Umbrella Trial (CTONG1702) (IASLC-WCLC 2026) - "This report presents data from seven cohorts: Sintilimab monotherapy: Cohort 14 (PD-L1 TPS ≥ 50%), Cohort 15 (PD-L1 TPS < 50% with TMB-High), Cohort 16 (PD-L1 TPS < 50% with KRAS/TP53 co-mutations); Sintilimab plus platinum-based chemotherapy: Cohort 17 (PD-L1 TPS < 1% non-squamous cell carcinoma, sintilimab + pemetrexed + cisplatin/carboplatin) and Cohort 18 ( PD-L1 TPS < 1% squamous cell carcinoma, sintilimab + gemcitabine + carboplatin); Sintilimab + fruquintinib: Cohort 22 (PD-L1 TPS < 50%) and Cohort 23 (PD-L1 TPS ≥ 50%). The most common adverse events was proteinuria. Conclusions : TMB-High seems to be a good predictor for long PFS and OS of sintilimab monotherapy; Sintilimab combined with fruquintinib showed prolonged PFS and OS, especially in PD-L1 ≥ 50%, suggesting a novel chemo-free regimen worth exploring."

Biomarker • IO biomarker • Metastases • Monotherapy • P2 data • Tumor mutational burden • Lung Cancer • Lung Non-Squamous Non-Small Cell Cancer • Non Small Cell Lung Cancer • Renal Disease • Solid Tumor • Squamous Cell Carcinoma • KRAS • TMB • TP53

S1701, A Randomized Phase 2 Trial of Carboplatin-Paclitaxel With and Without Ramucirumab in Patients With Locally Advanced, Recurrent, or Metastatic Thymic Carcinoma. (PubMed, JTO Clin Res Rep) - "Future research should consider exploring larger multicenter trials and other combinations to improve outcomes. Challenges in enrollment emphasize the need for innovative strategies and larger collaborations in rare malignancies such as thymic carcinoma."

Journal • Metastases • P2 data • Cardiovascular • Hematological Disorders • Neutropenia • Oncology • Solid Tumor • Thymic Carcinoma • Thymus Cancer

Rechallenge With Zongertinib After Trastuzumab Deruxtecan in HER2-Mutant Lung Cancer (IASLC-WCLC 2026) - "First-line combination therapy with cisplatin, pemetrexed, and pembrolizumab was initiated; however, the primary tumor progressed within 4 months. Subsequent treatments included docetaxel + ramucirumab, S1, and atezolizumab with progression-free survival (PFS) of 8, 1, and 1 months, respectively...After 7 months of Carboplatin + nab-paclitaxel treatment, owing to primary tumor enlargement, zongertinib was restarted as the eighth-line treatment...Conclusions : This report clearly demonstrates the complementary effects of the distinct mechanisms of action of zongertinib and T-DXd. Of particular interest, resistance to TKI therapy appeared reversible after intervening ADC treatment."

Lung Adenocarcinoma • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • ALK • BRAF • EGFR • FGFR3 • HER-2 • ROS1

Efficacy and Safety of Conventional and Low-dose Platinum Gemcitabine Combined With Sintilimab With Delayed Administration in First-line Treatment of Advanced Squamous Non-small Cell Lung Cancer (clinicaltrials.gov) - P2 | N=20 | Completed | Sponsor: People's Hospital of Quzhou | Phase classification: P4 ➔ P2

Phase classification • Lung Cancer • Lung Non-Small Cell Squamous Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Efficacy and safety of ramucirumab plus carboplatin and paclitaxel in untreated metastatic thymic carcinoma: RELEVENT phase II trial (NCT03921671). (PubMed, Ann Oncol) - P2 | "In previously untreated advanced TC, the addition of ramucirumab to carboplatin and paclitaxel showed the highest activity compared to historical controls, with a manageable safety profile. Despite the small number of patients, given the rarity of the disease, the trial results support the consideration of this combination as first-line treatment in TC."

Journal • Metastases • P2 data • Oncology • Solid Tumor • Thymic Carcinoma • Thymus Cancer

First-Line Chemoimmunotherapy and Chemotherapy Outcomes in RET Fusion-Positive Lung Cancer Patients in LIBRETTO-431 (IASLC-WCLC 2026) - "Methods : In the registrational, phase 3 LIBRETTO-431 study, RET fusion-positive lung cancer patients were randomized to selpercatinib or platinum doublet chemotherapy (carboplatin/cisplatin and pemetrexed), with or without pembrolizumab. Conclusions : In advanced RET fusion-positive lung cancers treated in this global, multicenter trial, outcomes with first-line chemoimmunotherapy and chemotherapy were not different. Using chemotherapy alone is a reasonable strategy for these oncogene-driven tumors."

Clinical • Lung Cancer • Oncology • Solid Tumor • PD-L1 • RET

First-Line Treatment of De Novo MET Amplification With High PD-L1 Expression in NSCLC: A Case Series (IASLC-WCLC 2026) - "The KUNGPENG study established the efficacy of vebreltinib in this setting—leading to its NMPA approval in China, the optimal first-line strategy for patients with concurrent MET amplification and high PD-L1 expression remains unclear...NGS revealed MET copy number gain (CN 6.17), and FISH confirmed clustered amplification.The first-line savolitinib started in July 12, 2024...The first-line chemo-immunotherapy with sintilizumab, nab-paclitaxel, and carboplatin, achieving a PR with a PFS of 8 months...best response is PR with PFS 6m.He received pemetrexed, carboplatin, and pembrolizumab for second-line therapy, achieving a durable PR till now more than 2 years .Case 4: 65-year-old male, heavy smoker...Biomarkers showed high PD-L1 (95%) and MET IHC (95%, 3+), with NGS revealing MET CN 3.8 and MET cluster amplification by FISH.He received first-line pemetrexed, carboplatin, and sintilimab for six cycles and then maintenance with pemetrexed+sintilimab achieving a PR with a..."

Clinical • IO biomarker • Cough • Interstitial Lung Disease • Lung Adenocarcinoma • Lung Cancer • Non Small Cell Lung Cancer • Pulmonary Disease • Respiratory Diseases • Solid Tumor • MET • PD-L1

LOXO-FRA-24001: A Study of Sofe-M in Participants With Selected Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=575 | Recruiting | Sponsor: Eli Lilly and Company | Trial completion date: Apr 2027 ➔ Jun 2029 | Trial primary completion date: Feb 2027 ➔ Jun 2029

First-in-human • Trial completion date • Trial primary completion date • Breast Cancer • Cervical Cancer • Colorectal Cancer • Endometrial Cancer • Hormone Receptor Positive Breast Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Ovarian Serous Adenocarcinoma • Pancreatic Cancer • Solid Tumor • Triple Negative Breast Cancer • Uterine Cancer

Sintilimab plus anlotinib and chemotherapy as first-line treatment for advanced malignant pleural mesothelioma (SACH-MPM): A prospective, single-arm, phase II trial. (ASCO 2026) - P2 | "Clinical Trial Registration Number: NCT05188859 Background: Standard first-line treatments for advanced malignant pleural mesothelioma (MPM) include platinum-pemetrexed with bevacizumab or nivolumab plus ipilimumab. While the addition of atezolizumab to chemotherapy and bevacizumab improved PFS in the BEAT-meso trial (9.2 vs. 7.6 m, HR 0.72), it failed to show an OS benefit...Pts received sintilimab (200 mg D1) and anlotinib (12 mg D1-14) plus chemotherapy (pemetrexed 500 mg/m² with cisplatin 75 mg/m² or carboplatin AUC 5, D1) Q3W for 4-6 cycles, followed by maintenance sintilimab, anlotinib, and pemetrexed until disease progression, intolerable toxicity, or up to 24 months... Sintilimab plus anlotinib and chemotherapy demonstrated superior ORR compared to historical controls with a manageable safety profile. The study met its primary endpoint, and the high 12-month PFS rate suggests a potential survival benefit. These findings support integrating a..."

Clinical • Metastases • P2 data • Cardiovascular • Hypertension • Malignant Pleural Mesothelioma • Mesothelioma • Pleural Mesothelioma • Pulmonary Embolism • Respiratory Diseases • Solid Tumor • FGFR

PD-1 Inhibitor (Sintilimab) Combined With Chemotherapy as Neoadjuvant Therapy in Advanced Ovarian Cancer: A Case Report. (PubMed, Clin Case Rep) - "In a patient with advanced ovarian cancer showing limited response to paclitaxel-carboplatin, adding sintilimab was associated with R0 cytoreduction and sustained disease-free status during olaparib-bevacizumab maintenance. This case provides a rationale for further investigation of PD-1 blockade as neoadjuvant therapy in carefully selected patients with suboptimal response to platinum-taxane chemotherapy."

Journal • Oncology • Ovarian Cancer • Solid Tumor

Cetuximab combined with weekly carboplatin/paclitaxel (CPT) or with immune checkpoint inhibitor (CICI) after progression on checkpoint inhibition in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) (ESMO 2026) - No abstract available

Checkpoint inhibition • Metastases • Head and Neck Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck

Nivolumab Plus Ipilimumab Versus EXTREME Regimen as First-Line Treatment for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck: The Final Results of CheckMate 651. (PubMed, J Clin Oncol) - P3 | "CheckMate 651 did not meet its primary end points of OS in the all randomly assigned or CPS ≥ 20 populations. Nivolumab plus ipilimumab showed a favorable safety profile compared with EXTREME. There continues to be a need for new therapies in patients with R/M SCCHN."

Journal • Head and Neck Cancer • Oncology • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • PD-L1

Induction chemotherapy effects on very advanced (T3/T4) human papillomavirus-related oropharyngeal cancer for participation in hypoxia-directed major de-escalation (30 Gy) definitive treatment trial. (ASCO 2024) - P2 | "ICT – carboplatin (AUC2), paclitaxel (90 mg/m2), and cetuximab (250 mg/m2 after 400 mg/m2 loading dose) weekly for 6 weeks...All patients to date were able to receive 2 cycles of cisplatin (100 mg/m2) without dose or treatment adjustment. Preliminary results suggest that ICT can allow more advanced tumors (T3/T4), that are typically excluded from de-escalation studies, to be de-escalated and may eliminate tumor hypoxia in a large proportion of cases, but a larger study is needed to confirm these results. Further followup of outcomes (2 year local control rate) is still needed."

Metastases • Head and Neck Cancer • Oncology • Oropharyngeal Cancer • Solid Tumor

S1701: A randomized phase II trial of carboplatin-paclitaxel with and without ramucirumab in patients with locally advanced, recurrent, or metastatic thymic carcinoma. (ASCO 2024) - "The addition of ramucirumab to CP led to higher response rates than CP alone. At this early analysis, PFS was not significantly improved; OS is pending. High-grade adverse events necessitate careful patient selection."

Clinical • Metastases • P2 data • Cardiovascular • Hematological Disorders • Neutropenia • Oncology • Solid Tumor • Thymic Carcinoma • Thymus Cancer

Relevent Trial: Updated Survival Outcomes of Ramucirumab in Combination With Chemotherapy in Untreated Advanced Thymic Carcinoma (IASLC-WCLC 2026) - P2 | "Introduction : The phase II RELEVENT trial (NCT03921671), evaluated the addition of the antiangiogenic ramucirumab to carboplatin and paclitaxel in previously untreated advanced thymic carcinoma (TC). These findings add valuable evidence to the limited prospective literature in advanced TC. Exploratory analyses suggest sustained disease control during maintenance, although confirmation in larger cohorts is warranted."

Combination therapy • Metastases • Oncology • Solid Tumor • Thymic Carcinoma • Thymus Cancer • BRCA1 • SETD2 • TET2

Efficacy and safety of ramucirumab plus carboplatin and paclitaxel in untreated metastatic thymic carcinoma: RELEVENT phase II trial (ESMO 2023) - P2 | "All pts received R 10 mg/kg, CBDCA AUC5 and PTX 200 mg/m2 d1q21 for 6 cycles, followed by R 10 mg/kg maintenance until disease progression or intolerable toxicity. Conclusions In previously untreated advanced TC, the addition of R to CBDCA and PTX showed highest activity compared to historical controls, with manageable safety profile. Despite the small number of pts, given the rarity of the disease, these results support the use of this combination as first line treatment in TC."

Clinical • Late-breaking abstract • Metastases • P2 data • Oncology • Solid Tumor • Thymic Carcinoma • Thymus Cancer

Neoadjuvant Sintilimab Plus Chemotherapy for cT2N0M0 Oral Squamous Cell Carcinoma (clinicaltrials.gov) - P3 | N=300 | Not yet recruiting | Sponsor: caohaotian

Head-to-Head • New P3 trial • Head and Neck Cancer • Oncology • Oral Cancer • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck

Audiologic Surveillance Gaps and Hearing Threshold Shifts Following IMRT for Head and Neck Cancer (ASTRO 2026) - "Patients were grouped as receiving radiation alone (RT; n=869) or radiation with systemic therapy (RTS; n=826; cisplatin, carboplatin, cetuximab, or combinations), sub-classified as concurrent (RTS-C; n=333) or sequential (RTS-S; n=493). Fewer than one-third of HNC IMRT patients underwent institutional audiologic testing, and fewer than 7% had completed audiometric evaluation in per ACS guidelines. Threshold shifts were greatest among RTS-C patients, the least consistently screened group. These findings highlight gaps in audiologic surveillance among HNC patients receiving IMRT and underscore the need for standardized, guideline-based protocols, particularly for patients receiving concurrent platinum-based chemoradiation."

Head and Neck Cancer • Oncology • Solid Tumor

Preliminary results from the multicenter, randomized phase III trial (SCIENCE): Comparing chemotherapy plus sintilimab and chemoradiotherapy plus sintilimab versus chemoradiotherapy for neoadjuvant treatment in resectable locally advanced esophageal squamous cell carcinoma. (ASCO-GI 2025) - P3 | "Participants were randomized in a 1:1:1 ratio to one of three neoadjuvant treatment groups: Group A: Sintilimab combined with nCT (nab-paclitaxel plus carboplatin) for two cycles. This Phase III trial demonstrates that nCRT, with or without Sintilimab, significantly enhances pCR rates compared to nCT with Sintilimab in LA-ESCC, without increasing surgical risks. Ongoing monitoring of EFS is necessary to validate these results."

Clinical • Late-breaking abstract • Metastases • P3 data • P3 data: top line • Esophageal Cancer • Esophageal Squamous Cell Carcinoma • Gastrointestinal Cancer • Oncology

Paclitaxel, carboplatin, and cetuximab induction chemotherapy for locally advanced head and neck squamous cell carcinoma: A retrospective evaluation of treatment outcomes and safety. (PubMed, Curr Ther Res Clin Exp) - "PCE achieved an 82.7% response rate, CRT completion in 51 of 52 patients (98.1%), and significantly higher cisplatin ≥200 mg/m² achievement (86.5% vs. 59.2%, p = 0.002). PFS was longer in the PCE group after limited adjustment, whereas OS did not differ significantly. Given the retrospective, nonrandomized design, residual confounding, and shorter follow-up in the PCE group, these findings are hypothesis-generating and require confirmation in larger, prospective studies."

Journal • Retrospective data • Head and Neck Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck

Randomized phase III study of first-line selpercatinib versus chemotherapy and pembrolizumab in RET fusion-positive NSCLC (ESMO 2023) - P3 | "Methods LIBRETTO-431 (NCT04194944) is a randomized, open-label, phase 3 trial comparing first-line selpercatinib vs chemotherapy (cisplatin/carboplatin + pemetrexed) +/- pembrolizumab. LIBRETTO-431 is the first randomized study to demonstrate superior PFS with a targeted therapy vs chemotherapy + a checkpoint inhibitor in a biomarker selected patient population. These data support comprehensive genomic testing at diagnosis and treatment with first-line selpercatinib in patients with advanced RET+ NSCLC."

Clinical • Late-breaking abstract • P3 data • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • RET

Rh-Endostatin + Sintilimab as First-Line Therapy for EGFR/ALK-Negative Squamous NSCLC: A Single-Arm, Multicenter Phase II Clinical Study (IASLC-WCLC 2026) - "During the induction phase, patients received rh-endostatin (210 mg continuous intravenous infusion, days 1-3), sintilimab (200 mg), and chemotherapy (nab-paclitaxel + carboplatin/cisplatin) every 3 weeks for 4-6 cycles. Secondary endpoints included overall survival (OS), duration of response (DoR), disease control rate (DCR), and safety profile. Exploratory analyses evaluated potential biomarkers and patient-reported quality of life."

Clinical • IO biomarker • P2 data • Lung Cancer • Lung Non-Small Cell Squamous Cancer • Non Small Cell Lung Cancer • Solid Tumor • ALK • EGFR

Cetuximab combined with Pembrolizumab or Finotonlimab and Chemotherapy in R/M HNSCC: an Open-label, Randomized, Prospective, Multicenter phase III Trial (ChiCTR) - P3 | N=316 | Not yet recruiting | Sponsor: Fudan University Shanghai Cancer Center; Fudan University Shanghai Cancer Center

New P3 trial • Head and Neck Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck

Two cycles versus three cycles of neoadjuvant sintilimab plus platinum-doublet chemotherapy in patients with resectable non-small-cell lung cancer (neoSCORE): A randomized, single center, two-arm phase II trial. (ASCO 2022) - P2 | "Eligible patients were randomly assigned to two or three cycles of neoadjuvant treatment with intravenous sintilimab (200 mg) plus carboplatin (area under curve 5) and nab-paclitaxel (260mg/m2, for squamous) or pemetrexed (500mg/m2, for non-squamous) on day 1 of three-week cycle. It is the first randomized study comparing different treatment periods of immuno-chemotherapy in the neoadjuvant setting. Three cycles neoadjuvant treatment achieved a numerically higher MPR rate compared with two cycles. Patients with squamous lung cancer obtained a better MPR rate compared with non-squamous subtype."

Clinical • IO biomarker • P2 data • Immune Modulation • Inflammation • Lung Cancer • Lung Non-Squamous Non-Small Cell Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma • PD-L1